Skip to main content
. 2018 Dec 27;15:127–135. doi: 10.2147/NDT.S186865

Table 2.

The overall pooled SMD for cerebrolysin treatment across all included studies

Clinical outcomes Number of studies Pooled SMDs 95% CI P-value Heterogeneity
I2 (%) Q P-value heterogeneity
GOS 16 0.3 0.18 to 0.42 <0.001 87.8 123.32 <0.001
mRS 16 −0.29 −0.42 to 0.16 0.05 89.6 143.67 <0.001

Abbreviations: GOS, Glasgow Outcome Scale; mRS, modified Rankin Scale; SMD, standardized mean difference.